Botulinum toxin treatment for limb spasticity in childhood cerebral palsy

Vito Pavone, Gianluca Testa, Domenico A. Restivo, Luca Cannavò, Giuseppe Condorelli, Nicola M. Portinaro, Giuseppe Sessa

Research output: Contribution to journalArticlepeer-review


CP is the most common cause of chronic disability in childhood occurring in 2-2.5/1000 births. It is a severe disorder and a significant number of patients present cognitive delay and difficulty in walking. The use of botulinum toxin (BTX) has become a popular treatment for CP especially for spastic and dystonic muscles while avoiding deformity and pain. Moreover, the combination of physiotherapy, casting, orthotics and injection of BTX may delay or decrease the need for surgical intervention while reserving single-event, multi-level surgery for fixed musculotendinous contractures and bony deformities in older children. This report highlights the utility of BTX in the treatment of cerebral palsy in children. We include techniques for administration, side effects, and possible resistance as well as specific use in the upper and lower limbs muscles.

Original languageEnglish
Article number29
JournalFrontiers in Pharmacology
Issue numberFEB
Publication statusPublished - Feb 19 2016


  • Botulinum toxin A
  • Cerebral palsy
  • Key-muscle
  • Multi-level treatment
  • Resistance

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Botulinum toxin treatment for limb spasticity in childhood cerebral palsy'. Together they form a unique fingerprint.

Cite this